Cancer lab wins purchasing deal

FORT MYERS — Cancer-testing firm NeoGenomics entered into a group-purchasing agreement with Premier, which represents 3,600 hospitals.

The three-year agreement will make NeoGenomics the first specialized oncology laboratory to be a preferred in-network option for Premier hospitals and 120,000 other providers, including cancer centers, pathology groups and physicians in the U.S., the company says. Terms of the deal were not disclosed.

“We are extremely honored to have been selected by Premier to be their first specialized oncology reference lab,” says Douglas VanOort, NeoGenomics chairman and CEO, in a statement. “Premier's membership includes more than half the hospitals in the United States and many important oncology and pathology practices that we believe will benefit from our full line of cancer genetic testing services.”

Headquartered with a lab in Fort Myers, NeoGenomics also operates labs in Tampa, Nashville, Tenn., and California. The company's stock is publicly traded (symbol: NEO; recent price: $6.29).